Stockreport

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 [Yahoo! Finance]

SAB Biotherapeutics, Inc.  (SABS) 
PDF agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS , SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO's lead program in clinical dev [Read more]